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Inhalation therapy is the mainstream treatment for bronchial
asthma and chronic obstructive pulmonary disease (COPD). At pre-
sent, hand-held devices for inhalation therapy, including pressur-
ized metered dose inhalers (pMDIs), dry powder inhalers (DPIs)
and Respimat® soft mist inhaler (SMI) are used. In pMDIs and Respi-
mat® SMI, the spray velocity is one of the most important aerosol
characteristics affecting the deposition in the lung,1 thereby
providing 1 criterion for the selection of drug preparations for clin-
ical cases. Therefore, the aerosol spray velocities of seven pMDIs
containing hydroﬂuoroalkane (HFA) propellant and one Respimat®
SMI weremeasured using particle image velocimetry2 (PIV), a well-
established method in ﬂuid dynamics.
Four pMDIs contain short-acting beta-agonist (SABA), three
pMDIs are for inhaled corticosteroids (ICSs), and Respimat® SMI is
for tiotropium. SABAs include salbutamol (Salbutamol$GSK and
Salbutamol$3M), fenoterol, and procaterol. ICSs include ﬂuticasone
propionate (FP), beclomethasone dipropionate (BDP), and cicleso-
nide (CIC).
At each measurement the pMDIs were shakenwell and then the
drug aerosols were sprayed approximately ten times in the air. Af-
ter conﬁrming that the aerosol spray was stable, the average of 30
spray velocities (10 sprays/device x 3 devices) per each product was
used for analysis. In this study, Respimat® SMI was measured
without shaking.
Using PIV, the velocity of the tip of the drug aerosol cloud
sprayed in the atmosphere was measured at positions 80-/100-
mm from the end of the nozzle of the pMDIs and SMI in view of
closed-mouth and open-mouth methods. Brieﬂy, spraying the
drug aerosol from an inhaler against the laser (Pegasus-PIV, New
Wave Research, CA, USA), the movement of the aerosol cloud is
lighted up by a thin laser sheet light and photographed at 3000
frames per second using a CCD high-resolution camera (FASTCAM
SA3, Photron, Tokyo, Japan). Using the calibration vision set out in
a longitudinal direction, the tip of the aerosol cloud is read by
viewing the acquired image. Figure 1 shows a series of images of
aerosol clouds.
The location (mm) of the tip of the aerosol cloud is plotted on an
abscissa axis and the relative time (ms) in which 0 indicates that of
the ﬁrst appearance of the tip in a series of images is plotted on the
longitudinal axis. The velocity at each point is interpolated by poly-
nomial regression. For example, the velocity at position 80-mm isPeer review under responsibility of Japanese Society of Allergology.
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sion shown below.
“1/(relative time at position 80.5 mmrelative time at position
79.5)”
The mean aerosol velocities of all inhalation drug products
tested in this study are shown in Figure 2. There are large differ-
ences in the aerosol velocity among pMDIs for SABA. The velocity
of the pMDI for Salbutamol$GSK was the fastest (8.91/7.34 m/s at
positions 80-/100-mm distant from the end of nozzle, respectively)
and that of the pMDI for fenoterol was the slowest (2.47/1.71 m/s at
positions 80-/100-mm distant from the end of nozzle, respectively)
of all the pMDIs for SABA.
The aerosol velocity of the pMDI for FP (9.15/7.80 m/s at posi-
tions 80-/100-mm from the end of nozzle) was higher than those
of pMDIs for BDP and CIC. Respimat® SMI for tiotropium generated
an aerosol spray of the slowest velocity (0.84/0.72 m/s at positions
80-/100-mm distant from the end of nozzle) of all the products
tested in this study.
All inhalation drug products used in this study are clinically
used in Japan. Although other factors than spray velocity have not
been evaluated, this study is the ﬁrst report comparing the spray
velocities of pMDIs for SABA and ICS and Respimat® SMI for tio-
tropium using a similar method, temporally and spatially.
As shown in Results, the aerosol velocity of pMDI for fenoterol
was slower than those of the other 3 pMDIs for SABA. Usmani
et al.3 reported that faster inspiratory ﬂows decreased total lung
deposition and increased oropharyngeal deposition for larger parti-
cles, with less bronchodilation. Therefore, in terms of spray veloc-
ity, fenoterol was the most favorable bronchodilator.
pMDIs for ICS are divisible into two groups according to the
spray velocity. As shown in Results, pMDIs for BDP and CIC generate
almost the same velocity, which was slower than that of pMDI for
FP. As I previously reported that the particle size distribution of
the aerosols generated from these pMDIs had the same bi-modal
distribution,4 I infer that the inhalers for BDP and CIC are the
same. In addition, these ﬁndings explain why inhalation from
pMDIs for BDP5 and CIC6 results in higher pulmonary deposition
than that from pMDI for FP,7 especially in the peripheral regions
of the lung.
I previously reported that the aerosol velocity of pMDI for the
FP/formoterol combination agent was slower than that of pMDI
for the FP/salmeterol combination.8 Thus, I measured the spray ve-
locity of all HFA-pMDI preparations used in Japan. Consequently, I
found a large difference in the aerosol velocity of HFA-pMDIs,vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. A series of real images of an aerosol cloud.
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Fig. 2. Spray velocities of four pMDIs for SABA, three pMDIs for ICS and Respimat® SMI
for tiotropium.
Letter to the Editor / Allergology International 64 (2015) 390e392 391although most HFA-pMDIs have a smaller delivery oriﬁce that may
result in a more slowly delivered aerosol plume, compared with
chloroﬂuorocarbons-driven pMDIs.
As shown in Results, Respimat® SMI for tiotropium generated
the slowest spray velocity of all inhalation drug products used in
this study. It has also been reported that Respimat® SMI generates
amuch longer spray duration than other pMDIs.9 Additionally, I and
Ichinose have reported that the particle size distribution of aerosols
generated from the SMI showed a bi-modal distribution, with
peaks at around 0.5 mm and 5 mm.10 Therefore, these ﬁndings sug-
gest that Respimat® SMI is the best portable inhaler for the treat-
ment of central and peripheral airways.Acknowledgment
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